BGMS - Cyclacel Pharmaceuticals, Inc.

0.95
-0.010   -1.063%

Share volume: 18,854
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$0.96
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.94%
1 Month
-5.94%
3 Months
-44.61%
6 Months
-86.52%
1 Year
198.74%
2 Year
-61.85%
Key data
Stock price
$0.95
P/E Ratio 
0.00
DAY RANGE
$0.95 - $0.99
EPS 
-$2.47
52 WEEK RANGE
$0.17 - $19.87
52 WEEK CHANGE
$208.84
MARKET CAP 
11.061 M
YIELD 
N/A
SHARES OUTSTANDING 
4.900 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$16,462
AVERAGE 30 VOLUME 
$164,229
Company detail
CEO: Spiro Rombotis
Region: US
Website: cyclacel.com
Employees: 14
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.

Recent news